International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients

Journal of Cystic Fibrosis

Volumn 10, Issue 6, 2011, Pages 443-452

  Borowitz, Drucy ^a   Stevens, Christopher ^b   Brettman, Lee R ^b   Campion, Marilyn ^b   Chatfield, Barbara ^c   Cipolli, Marco ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b Alnara Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Cystic fibrosis; Malabsorption; Pancreatic enzymes; Pancreatic insufficiency

Indexed keywords

LIPROTAMASE; NITROGEN; PANCREAS ENZYME; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FECES ANALYSIS; FEMALE; HUMAN; LIPID ABSORPTION; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; PANCREAS INSUFFICIENCY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STEATORRHEA;

ADOLESCENT; ADULT; AMYLASES; CHILD; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; ENZYME REPLACEMENT THERAPY; EXOCRINE PANCREATIC INSUFFICIENCY; FEMALE; HUMANS; INTERNATIONAL COOPERATION; LIPASE; MALE; PEPTIDE HYDROLASES; YOUNG ADULT;

EID: 81455141412     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.07.001     Document Type: Article

References (31)

1. Borowitz D., Baker S.S., Duffy L., Baker R.D., Fitzpatrick L., Gyamfi J., et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 2004, 145:322-326.
2. Borowitz D.S., Grand R.J., Durie P.R. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. J Pediatr 1995, 127:681-684.
3. Borowitz D., Parad R.B., Sharp J.K., Sabadosa K.A., Robinson K.A., Rock M.J., et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 2009, 155:S106-S116.
4. Layer P., Keller J. Pancreatic enzymes: secretion and luminal nutrient digestion in health and disease. J Clin Gastroenterol 1999, 28:3-10.
5. http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4402s1-02-FDA-Cherney%20.pdf.
6. Whitehead A.M. Study to compare the enzyme activity, acid resistance and dissolution characteristics of currently available pancreatic enzyme preparations. Pharm Weekbl Sci 1988, 10:12-16.
7. Kraisinger M., Hochhaus G., Stecenko A., Bowser E., Hendeles L. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol 1994, 34:158-166.
8. O'Hare M.M., McMaster C., Dodge J.A. Stated versus actual lipase activity in pancreatic enzyme supplements: implications for clinical use. J Pediatr Gastroenterol Nutr 1995, 21:59-63.
9. Kuhn R., Eyting S., Henniges F., Potthoff A. In vitro comparison of physical parameters, enzyme activity, acid resistance and pH dissolution characteristics of enteric-coated pancreatic enzyme preparations: implications for clinical variability and pharmacy substitution. J Pediatr Pharmacol Ther 2007, 12:115-128.
10. Freiman J.P., FitzSimmons S.C. Colonic strictures in patients with cystic fibrosis: results of a survey of 114 cystic fibrosis care centers in the United States. J Pediatr Gastroenterol Nutr 1996, 22:153-156.
11. Smyth R.L., Ashby D., O'Hea U., Burrows E., Lewis P., van Velzen D., et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet 1995, 346:1247-1251.
12. FitzSimmons S.C., Burkhart G.A., Borowitz D., Grand R.J., Hammerstrom T., Durie P.R., et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997, 336:1283-1289.
13. Kermanshahi H., Maenz D.D., Classen H.L. Stability of porcine and microbial lipases to conditions that approximate the small intestine of young birds. Poult Sci 1998, 77:1671-1677.
14. Raimondo M., DiMagno E.P. Lipolytic activity of bacterial lipase survives better than that of porcine lipase in human gastric and duodenal content. Gastroenterology 1994, 107:231-235.
15. Basu S.K., Govardhan C.P., Jung C.W., Margolin A.L. Protein crystals for the delivery of biopharmaceuticals. Expert Opin Biol Ther 2004, 4:301-317.
16. Shenoy B., Wang Y., Shan W., Margolin A.L. Stability of crystalline proteins. Biotechnol Bioeng 2001, 73:358-369.
17. Stern R.C., Eisenberg J.D., Wagener J.S., Ahrens R., Rock M., doPico G., et al. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. Am J Gastroenterol 2000, 95:1932-1938.
18. Wooldridge J.L., Heubi J.E., Amaro-Galvez R., Boas S.R., Blake K.V., Nasr S.Z., et al. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros 2009, 8:405-417.
19. Trapnell B.C., Maguiness K., Graff G.R., Boyd D., Beckmann K., Caras S. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros 2009, 8:370-377.
20. Drug name: Pancreaze (pancrelipase) October 31 2010, CenterWatch, Available from:. http://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=1094.
21. Borowitz D., Goss C.H., Stevens C., Hayes D., Newman L., O'Rourke A., et al. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. Pancreas 2006, 32:258-263.
22. Borowitz D., Goss C.H., Limauro S., Konstan M.W., Blake K., Casey S., et al. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. J Pediatr 2006, 149:658-662.
23. Korpi-Steiner N.L., Ward J.N., Kumar V., McConnell J.P. Comparative analysis of fecal fat quantitation via nuclear magnetic resonance spectroscopy (1H NMR) and gravimetry. Clin Chim Acta 2009, 400:33-36.
24. Cystic Fibrosis Foundation Patient Registry: 2008 Annual Data Report 2008, Bethesda, Maryland.
25. Stevens J.C., Maguiness K.M., Hollingsworth J., Heilman D.K., Chong S.K. Pancreatic enzyme supplementation in cystic fibrosis patients before and after fibrosing colonopathy. J Pediatr Gastroenterol Nutr 1998, 26:80-84.
26. van Velzen D., Ball L.M., Dezfulian A.R., Southgate A., Howard C.V. Comparative and experimental pathology of fibrosing colonopathy. Postgrad Med J 1996, 72(Suppl. 2):S39-S48.
27. Sinaasappel M., Stern M., Littlewood J., Wolfe S., Steinkamp G., Heijerman H.G., et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 2002, 1:51-75.
28. Durie P., Kalnins D., Ellis L. Uses and abuses of enzyme therapy in cystic fibrosis. J R Soc Med 1998, 91(Suppl. 34):2-13.
29. Weber A.M., Roy C.C. Intraduodenal events in cystic fibrosis. J Pediatr Gastroenterol Nutr 1984, 3(Suppl. 1):S113-S119.
30. Navarro V.J., Senior John R. Drug-related hepatotoxicity. N Engl J Med 2006, 354:731-739.
31. Goss G.H., Mayer-Hamblett N., Kronmal R.A., Williams J., Ramsey B.W. Laboratory parameter profiles among patients with cystic fibrosis. J Cyst Fibros 2007, 6:117-123.